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Peripheral arterial disease (PAD) is common in hemodialysis patients and predicts a poor prognosis. We conducted a prospective
cohortstudytoidentifyriskfactorsforPADincludingskinperfusionpressure(SPP)inhemodialysis patients. Thecohortincluded
373 hemodialysis patients among 548 patients who received hemodialysis at Oyokyo Kidney Research Institute, Hirosaki, Japan
from August 2008 to December 2010. The endpoints were lower limb survival (peripheral angioplasty or amputation events)
and overall survival of 2 years. Our results showed that <70mmHg SPP was a poor prognosis for the lower limb survival and
overall survival. We also identiﬁed age, history of cardiovascular disease, presence of diabetes mellitus, smoking history, and SPP
<70mmHg as independent risk factors for lower limb survival and overall survival. Then, we constructed risk criteria using the
signiﬁcantly independent risk factors. We can clearly stratify lower limb survival and overall survival of the hemodialysis patients
into 3 groups. Although the observation period is short, we conclude that SPP value has the potential to be a risk factor that
predicts both lower limb survival and the prognosis of hemodialysis patients.
1.Introduction
Peripheral arterial disease (PAD) is common in hemodialysis
patients and predicts a poor prognosis [1]. Data from the
Dialysis Outcomes and Practice Patterns Study have shown
that PAD is associated with an increased risk for all-
cause mortality and cardiovascular disease (CVD) [2]. Early
detection of PAD is important to improve the prognosis in
hemodialysis patients.
Various noninvasive methods of ankle brachial pressure
index (ABI), toe blood pressure index (TBI), and transcu-
taneous oxygen pressure (tcPO2) have been widely used to
diagnose PAD. An ABI is currently used worldwide for
evaluating PAD; a <0.9 value has >98% speciﬁcity for
detecting PAD. However, high ABI values of >1.3 are
common in patients with diabetes mellitus (DM) or renal
failure, because they may have calciﬁcation in lower leg
artery, causing a falsely raised ABI [3]. False negative ABI
results occur in 17%–24% of limbs of DM and hemodial-
ysis patients [4, 5]. In contrast, measuring skin perfusion
pressure (SPP) using laser Doppler is a noninvasive method
that measures microcirculatory pressure of the artery at the
skin level. It can detect the movement of red blood cells by
slowly decreasing the inﬂation-cuﬀ pressure at the site of
measurement. SPP has proven to be beneﬁcial for assessing
theischemicseverityoflowerlimb[6,7],selectingofsuitable2 International Journal of Nephrology
degree of amputation [8, 9], and useful for judgment of
likelihood that ischemic foot ulcers will recover [10, 11]. SPP
measurementshaveadvantagesforpredictingwoundhealing
at the amputation edge in chronic critical limb ischemia with
ac u t o ﬀ value of <30mmHg [12]. Okamoto et al. reported
the superiority of SPP measurements for detecting PAD in
hemodialysis patients with a cutoﬀ value of 50mmHg [13].
Because SPP indicates the ﬁnal pathway of capillary ﬂow
through the skin with a laser Doppler probe, it has potential
to determine severe limb ischemia status with calciﬁcation in
hemodialysis patients.
Chronic kidney disease (CKD) and PAD independently
predict mortality. Both CKD and PAD patients have a signif-
icantly higher risk for death (odds ratio, 2.4) [14] and long-
termsurvivalisdismalformajorlowerextremityamputation
patients with end-stage renal disease [15]. However, not
much is known about SPP values for prognosis, and no
attempts have been made to classify the multiple risks of
PAD patients undergoing hemodialysis. In this study, we
hypothesized that SPP value has potential to predict patient’s
prognosis, and we determined the SPP cutoﬀ value for the
lower limb survival and overall survival and the PAD risk
classiﬁcation for hemodialysis patients.
2.MaterialsandMethods
2.1. Subjects. From August 2008 to December 2010, 548
patients underwent hemodialysis at the Oyokyo Kidney
Research Institute, Hirosaki, Japan. Among these, 373
hemodialysis patients who agreed to enter the present study
were enrolled as the cohort. We excluded these patients
who were not able to measure because of restless leg
syndrome or out of follow-up, or refused to measure SPP.
WemeasuredSPPinAugust2008andprospectivelyobserved
lower limb survival (peripheral angioplasty or amputation)
and overall survival for 2 years. This study was approved
by the institutional ethical committee of Oyokyo Kidney
Research Institute. Informed consent was obtained from all
patients.
2.2. SPP Measurements. SPP measurements of the soles of
the feet were conducted 1h after the hemodialysis session.
SPP was measured with a laser Doppler probe enclosed
within the bladder and a cuﬀ wrapped around the patient’s
foot sole (foot arch) using SensiLase PAD3000 (Kaneka
Medix Corp., Osaka, Japan). The patients were positioned
in a supine position at room temperature [16]. To evaluate
i s c h e m i cs t a t u so fb o t hl e gs ,a na v e ra g eo f2f e e tw a sr e ga r d e d
as the SPP value for each patient.
2.3. Patient Classiﬁcation. We measured SPP in 35 healthy
subjects (mean age: 50.8 ± 7.9 years, range: 38–76 years,
number smoking: 20) to determine a SPP reference range.
The healthy subjects were free of DM, hypertension, hyper-
lipidemia, or other diseases. We considered an SPP value of
50 and 70 as cutoﬀ values, because SPP from the 35 healthy
subjects showed an average value of 75.3 ± 9.2mmHg,and
Okamoto et al. [13]r e p o r t e d7 4 .8 ± 28.5 as a healthy SPP
value (n = 26; age, 59 ± 10.7 years). Based on a healthy
SPP value, we categorized the patients into three SPP groups:
Group 1, <50; Group 2, 50 ≤ SPP < 70; and Group 3,
SPP ≥ 7 0 .Af o o tS P P< 50mmHg was candidate for PAD
treatment. We started anticoagulant or antiplatelet treat-
ment and performed PAD examination (digital subtraction
angiography). If there were stenotic lesions, percutaneous
transluminal angioplasty was performed.
2.4. Evaluation. The background clinical data, gender, con-
comitant drugs, smoking habit, and incidences of periph-
eral angioplasty or amputation were compared among the
groups using the chi-square test. Age and other biochemical
parameters were expressed as mean ± SD, and statistical
diﬀerencesweredeterminedbytheoverallANOVA,Student’s
t-test, or chi-square analysis. Cumulative lower limb survival
and overall survival rates were plotted using the Kaplan-
Meier method, and the intergroup diﬀerences were tested
with the log-rank test. P<0.05 was considered signiﬁcant.
A Cox regression model, adjusted for these factors, was
also performed. The data used in the analyses included
age, gender, dialysis duration, concomitant drugs (activated
vitamin D, anticoagulants, or antiplatelet drugs), presence
of CVD (heart failure, myocardial infarction, and angina
pectoris), DM, SPP value, and smoking. Based on the
independent risk factors identiﬁed by the Cox regression
analysis, we determined the risk classiﬁcation for lower limb
survival and overall survival by the numbers of risk factors.
All analyses were performed using SPSS ver. 12.0 (SPSS Inc.,
Chicago, IL, USA).
3. Results
Table 1 shows the characteristics of the 373 patients. Signif-
icant diﬀerences were observed among the groups for the
presence of CVD, DM, use of activated vitamin D, use of
anticoagulant or antiplatelet drugs, peripheral angioplasty
or amputation events, and cause of death, but there were
no diﬀerences in cause of deaths. Figure 1 shows lower limb
survival and overall survival in the three groups. Group 1
(SPP < 50) showed poor lower limb survival compared to
that in the other groups. Group 2 (50 ≤ SPP < 70) showed
better survival compared to that in Group 1 (P<0.0001),
but a poor prognosis for lower limb survival compared to
that in Group 3 (SPP ≥ 70) (P = 0.0005). No signiﬁcant
diﬀerence in overall survival was observed between Groups
1a n d2( P = 0.2519). From these results, we recategorized
the patients characteristics with an SPP < 70 (Groups 1
and 2) and >70 (Group 3) (Table 2). The numbers of
patients with CVD, DM, use of activated vitamin D, use of
anticoagulant or antiplatelet drugs, peripheral angioplasty
or amputation events, or death were signiﬁcantly higher in
Groups 1 and 2 than those in Group 3. Lower limb survival
and overall survival were signiﬁcantly poorer in Groups 1
and 2 compared with those in Group 3 (Figure 2). The Cox
regressionanalysisrevealedthatanSPP<70andthepresence
of CVD, DM, and smoking were independent factors for
lower limb survival. Age ≥ 71.4 years, an SPP < 70, and
the presence of DM and smoking were independent factors
for overall survival (Table 3). We used average of SPP valeInternational Journal of Nephrology 3
Table 1:Characteristicsofthe373hemodialysispatients.Wecategorizedthepatientsintothreeskinperfusionpressure(SPP)groups:Group
1, <50; Group 2, 50 ≤ SPP < 70; and Group 3, SPP ≥ 70, based on a healthy SPP value from volunteers. P value refers to overall ANOVA or
chi-square analysis.
ALL Group 1 Group 2 Group 3 P value
SPP < 50 50 ≤ SPP < 70 SPP ≥ 70 (ANOVA)
n 373 30 (8%) 84 (23%) 259 (69%)
Age 71.4 ±9.77 1 .5 ±11.47 2 .6 ±11.17 1 .0 ±9.0 0.437
Gender (M/F) 207/166 15/15 50/34 142/117 0.617
Dialysis duration (Month) 100.4 ±77.1 103.6 ±88.1 100.6 ±81.5 100.0 ±74.6 0.970
CVD (+) 164 (44%) 13 (43%) 48 (57%) 103 (40%) 0.020
DM (+) 171 (46%) 21 (70%) 48 (57%) 102 (39%) <0.001
Use of activated vitamin D (+) 267 (72%) 23 (77%) 56 (67%) 217 (73%) 0.003
Current smoking (+) 55 (15%) 6 (21%) 16(20%) 33(13%) <0.001
Baseline SPP (mmHg) 77.9 ±21.13 5 .6 ±8.26 1 .0 ±5.78 8 .3 ±14.6 <0.001
Use of anticoagulant, antiplatelet 173 (46%) 20 (67%) 66 (79%) 87 (34%) <0.001
Periferal angioplasty 11 (2.9%) 6 (20%) 4 (4.8%) 1 (0.4%) <0.001
Amputation 6 (1.6%) 5 (17%) 1 (1.2%) 0 (0%) <0.001
Death 53 (14%) 9 (30%) 16 (19%) 28 (11%) 0.006
CVD 23 4 8 11 0.055
I n f e c t i o n 1 0 037 0 .582
Cancer 10 1 3 6 0.804
Others 10 4 2 4 <0.001
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Figure 1: Lower limb survival and overall survival in the three groups. Patients were categorized according to the skin perfusion pressure
(SPP) value: Group 1, <50; Group 2, 50 ≤ SPP < 70; and Group 3, SPP ≥ 70. Group 1 showed poorer lower limb survival compared to other
groups. Group 2 showed better survival compared to Group 1 (P<0.0001) but a poor prognosis for lower limb survival compared to Group
3( P = 0.0005). No signiﬁcant diﬀerence in overall survival was observed between Groups 1 and 2 (P = 0.2519).
from both feet because the result from worst feet for lower
limb survival and overall survival showed similar outcomes
(Figure 3).
Basedon the independent risk factors,we categorizedthe
threegroupsaccordingtothenumberofriskfactors.Patients
with zero or one risk factor, two risk factors, and three or
four risk factors were regarded as low-risk, intermediate-
risk, and high-risk groups, respectively. Cumulative lower
limb survival and overall survival rates were plotted using
the Kaplan-Meier method according to the risk classiﬁcation
(Figure 4). Lower limb survival and overall survival at 1 and
2 years were signiﬁcantly lower in the high-risk group than4 International Journal of Nephrology
Table 2:Recategorizationofpatientcharacteristicswithaskinperfusionpressure(SPP)cutoﬀvalueof70mmHg.Werecategorizedpatients
into two SPP groups: Groups 1 and 2: <70 and Group 3: ≥70. P value refers to Student’s t-test or chi-square analysis.
Groups 1 and 2 Group 3 P value
SPP < 70 SPP ≥ 70 Group 1 and 2 versus 3
n 114 (31%) 259 (69%)
Age 72.3 ±11.17 1 .0 ±9.0 0.282
Gender (M/F) 65/49 142/117 0.695
Dialysis duration (Month) 101.4 ±82.9 100.0 ±74.6 0.875
CVD (+) 61 (54%) 103 (40%) 0.014
DM (+) 69 (61%) 102 (39%) < 0.001
Use of activated vitamin D (+) 79 (69%) 217 (73%) 0.001
Current smoking (+) 22 (20%) 33 (13%) 0.100
Baseline SPP (mmHg) 54.3 ±12.98 8 .3 ±14.6 < 0.001
Use of anticoagulant, antiplatelet 86 (75%) 87 (34%) < 0.001
Intervention or amputation 16 (14%) 1 (0.4%) < 0.001
Death 25 (22%) 28 (11%) 0.005
CVD 12 11 0.523
Infection 3 7 0.227
Cancer 4 6 0.614
Others 6 4 0.367
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Figure 2: Lower limb survival and overall survival in Groups 1 and 2 versus 3. Patients were recategorized according to their SPP values:
Groups 1 and 2: <70 and Group 3: SPP ≥ 70. Lower limb survival and overall survival were signiﬁcantly poorer in Groups 1 and 2 (P<
0.0001) compared with those in Group 3 (P = 0.0043).
those in the other groups (Table 4). Lower limb survival and
overall survival rates at 1 year were 83.0% and 85.7% and at
2 years were 76% and 61.2% in the high-risk group patients,
respectively.
4. Discussion
Both CKD and PAD patients have a signiﬁcantly higher risk
fordeath[14],andanearlydetectionofPADinhemodialysis
patients is extremely important. Because calciﬁcation in
lower leg arteries causes a false negative ABI, SPP is a
more sensitive and speciﬁc method for detecting PAD in
hemodialysis patients, and an SPP of 50mmHg has been
suggested as the PAD cutoﬀ value in these patients [13]. Our
result showed that Group 1 (SPP < 50) had high morbidity
and mortality with the 20% of amputation and 67% of
peripheral angioplasty. However, starting treatment from an
SPP of 50mmHg may be late in hemodialysis patients from
theviewpointofearlydetectionandinterpositiontoimprove
prognosis. We observed a better outcome for lower limbInternational Journal of Nephrology 5
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Figure 3: Lower limb survival and overall survival based on the worst foot SPP. Patients were categorized according to the worst foot SPP
value: <50, 50 ≤ SPP < 70, SPP ≥ 70. There were no major diﬀerences in lower limb survival and overall survival between worst foot SPP
and average of SPP. We used average of SPP for risk classiﬁcation analysis.
survival in Group 2 (50 ≤ SPP < 70) compared with that in
Group 1, but overall survival was not signiﬁcantly diﬀerent
between Groups 1 and 2 (SPP < 70) (P = 0.2519, Figure 1).
Because SPP reﬂects the ﬁnal capillary ﬂow though the skin,
an SPP < 70 may indicate systematic circulatory failure in
hemodialysis patients. When we compared Groups 1 and 2
with 3 (SPP ≥ 70), many critical parameters (presence of
CVD, DM, use of activated vitamin D, use of anticoagulant
or antiplatelet drugs, peripheral angioplasty or amputation
events, and death) were signiﬁcantly higher in Groups 1 and
2 than in 3. This suggests that patients with an SPP < 70 have
many risk factors for high mortality.
To address the worst foot inﬂuences, we analyzed lower
limb survival and overall survival, taking the SPP value
from worst foot sole (Figure 3). The diﬀerences of SPP
value between two feet were 11.1 ± 9.5mmHg (median 9.0,
maximum 56mmHg). The Kaplan-Meier curves showed
similar outcomes between worst foot and average of both
feet in survivals. It means that an average of SPP form both
feet is adequate marker to express general ischemic status of
hemodialysis patients, and an average of SPP < 70 is the risk
factor for lower limb survival and overall survival.
In an attempt to classify the multiple risks for prognosis
in hemodialysis patients using a Cox regression analysis, we
identiﬁed SPP < 70 as one of the independent risk factors for
lowerlimbsurvivalandprognosis,similartowell-knownrisk
factors for CVD or DM. A 2-year overall survival of 61.2% in
high-risk patients was remarkably low. These results suggest6 International Journal of Nephrology
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Figure 4: Lower limb survival and overall survival based on the risk classiﬁcation. We categorized the three groups according to the number
of risk factors based on a Cox regression analysis. Patients with zero or one risk factor, two risk factors, and three or four risk factors were
regarded as the low-risk, intermediate-risk, and high-risk groups, respectively. Lower limb survival and overall survival were signiﬁcantly
lower in the high-risk group than in the other groups.
Table 3: Independent risk factors for lower limb survival and
overall survival by Cox regression analysis. SPP < 70, presence of
CVD, DM, and smoking showed signiﬁcantly increase the risk for
lower limb survival (hazard ratios increased 4.722, 3.407, 4.050,
3.225 times, resp.), and age ≥ 71.4, SPP < 70, presence of DM, and
smoking showed signiﬁcantly increase the risk for overall survival
(hazard ratios increased 1.121, 1.209, 1.028, 4.521 times, resp.).
(∗HR: hazard ratio; ∗∗CI: conﬁdence interval).
Lower limb survival P value HR∗ 95%CI∗∗
SPP, ≥ 70 versus < 70 0.007 4.722 1.539 14.490
CVD, without versus
with 0.027 3.407 1.146 10.124
DM, without versus
with 0.035 4.050 1.102 14.876
Smoking, without
versus with 0.029 3.225 1.126 9.233
Overall survival P value HR 95%CI
Age, <71.4 versus
≥71.4 0.001 1.073 1.121 1.028
SPP, ≥70 versus <70 0.014 2.519 1.209 5.250
DM, without versus
with 0.042 2.239 1.028 4.875
Smoking, without
versus with 0.000 9.135 4.521 18.460
that early detection of peripheral hypoperfusion and higher
cut-oﬀ (SPP < 70, instead of <50) is critical to improve sur-
vival in hemodialysis patients in clinical practices.
Our study had several limitations. Because of the ob-
servational nature of this study at a single institute, our
observations cannot be generalized to the broader question
Table 4: Two-year outcomes of lower limb survival and overall
survival by risk classiﬁcation. Lower limb and overall survival were
signiﬁcantly lower in the high-risk group compared to those in the
other groups.
Lower limb survival 1 year 2 years
Low risk 99.5% 99.5%
Intermediate risk 95.6% 93.2%
High risk 83% 76%
Overall survival 1 year 2 years
Low risk 98.2% 96.9%
Intermediate risk 97.8% 84.2%
High risk 85.7% 61.2%
of prognostic potential of SPP in PAD patients who are
undergoing hemodialysis. We have no clear answer that why
SPP was not a signiﬁcant predictor of CVD-speciﬁc death
while SPP was a signiﬁcant predictor of overall death. It
maybecauseofshorttimefollow-uporresidualconfounding
and missing data may have introduced bias. However, this is
the ﬁrst study investigating an association between SPP and
mortality with a risk classiﬁcation. Therefore, our follow-
up study is needed to conﬁrm the relationship among
SPP, prognosis, and eﬃcacy of the risk classiﬁcation in
hemodialysis patients including other confounding: a mea-
sure of hypertension, number of hypertensive medications,
a measure of cholesterol and diabetes management, and
calcium, phosphate, and intact PTH levels.
In conclusion, we showed that an SPP < 70 was a risk
factor for lower limb survival and overall survival in he-
modialysis patients. To our knowledge, this is the ﬁrst
report to determine the SPP value for a prognosis and riskInternational Journal of Nephrology 7
classiﬁcation. The SPP value, age, presence of CVD, DM,
and smoking were associated with a poor prognosis. Early
detection of peripheral hypoperfusion and interposition is
critical to improve survival in hemodialysis patients.
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